Opinion of the Transparency Council – pomalidomide
At its meeting on 25 November 2024, the Transparency Council adopted opinion No. 182/2024 on changing the reimbursement category of medicinal products with the active substance pomalidomide
At its meeting on 25 November 2024, the Transparency Council adopted opinion No. 182/2024 on changing the reimbursement category of medicinal products with the active substance pomalidomide